NeuroNEXT

Dr. Merit Cudkowicz, Principal Investigator of the NeuroNEXT CCC, was interviewed on CBS News’ 60 Minutes on a feature about NFL star Tim Green coping with ALS. Her appearance begins at the 6:15 mark, and she discusses Mr. Green’s prognosis and treatment. 

The slide presentation from the 2018 NeuroNEXT Annual Meeting in Boston, MA October 18-19 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!

The dataset from the NN101 SMA project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov. 

NINDS has issued a press release regarding the publication of the NN102 SPRINT-MS study results in the New England Journal of Medicine. The press release quotes NINDS Director Walter J. Kroshetz, MD, saying the NN102 SPRINT-MS findings “provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options.”

The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.  

The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding. 

The University of Iowa highlighted NeuroNEXT achievements in two campus publications: Iowa Now provides an overview of the ways the Network is accelerating the clinical trials process, and The Daily Iowan focuses on the ways NeuroNEXT is bringing together clinical sites and coordinating centers to advance neurological trials.

In addition, the College of Public Health at the University of Iowa produced two videos highlighting NeuroNEXT research. One features Chris Coffey, NeuroNEXT DCC PI: 

The second video features Janel Barnes, a statistician at the DCC, who finished her PhD at the University of Iowa in 2017: 

The Clinical Trials Methodology Course (CTMC) has begun their 2018 Webinar Series. These webinars are open to all. The course focues on the desing of early stage clinical trials for investigators focused on neurological illness and injury. The full scheduled may be viewed online: https://siren.network/training/ctmc/ctmc-webinars. 

The NINDS Clinical Trials Methodology Course is supported by the NIH-NINDS: R25 NS088248 and is administered by the University of Michigan, the University of Iowa, and Los Angeles BioMed. Additional support is provided by the American Academy of Neurology.

Neuro Central Podcast NC Talks featured an interview with Dr. Robert Fox, PPI of the NN102 SPRINT-MS study. Dr. Fox discussed trial results with the podcasters at the American Academy of Neurlogy’s 70th Annual Meeting in Los Angeles, CA. 

The American Academy of Neurology (AAN) Annual Meeting will begin April 21 in Los Angeles, CA. The following NeuroNEXT events and presentations will take place:

• NeuroNEXT Meet & Greet Social: Please join us for a NeuroNEXT Meet & Greet on Monday, April 23 from 6:30-8pm PT at the O Hotel, 819 S. Flower St., Los Angeles. Light appetizers will be served and all Network affiliates are welcome.
• NN102 SPRINT-MS Plenary Presentation: Dr. Robert Fox will be presenting his project (“A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis”) on Tuesday, April 24, as part of the Clinical Trials Plenary Session that commences at 9:15am PT. Dr. Fox is expected to be presenting around 10:30am PT.
• NN103 Beat MG Abstract: Dr. Richard Nowak will present his NN103 Beat MG study abstract as part of the AAN Annual Meeting Emerging Science program. Titled “B Cell Targeted Treatment in Myasthenia Gravis (BeatMG) – A Phase 2 Trial of Rituximab in MG: Topline Results,” the poster #P4.478 will be at Poster Session IV on Wednesdsay, April 25 from 11:30am-7pm PT and the in-person presentation will be from 5:30-7pm PT. 

Please visit the AAN Annual Meeting site for more information on the plenary sessions or emerging science program. 

Related Projects: 

NN102 SPRINT-MS

NN103 Beat MG